Healthcare / BiotechnologyKOSDAQ
$6580.00
-130.00 (-1.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$25.0B
P/E
41.9x
↑EV/EBITDA
12.0x
↓ROE
1.7%
↑Gross Margin
24.8%
↓Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.6%
FCF CAGR
—
FCF margin
4.0%
FCF / Net income
1.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.99B · net income $598.2M · FCF $1.05B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.99B | $25.99B | $23.80B | $25.56B | $25.50B |
| Net Income | $598.2M | $598.2M | $-1.77B | $-679.7M | $1.70B |
| EBITDA | $3.48B | $3.48B | $990.0M | $2.67B | $5.48B |
| EPS | 157.00 | 157.00 | -466.00 | -179.00 | 448.00 |
| Gross Margin | 24.8% | 24.8% | 17.0% | 19.0% | 18.8% |
| Operating Margin | 2.7% | 2.7% | -6.5% | -2.7% | -1.3% |
| Net Margin | 2.3% | 2.3% | -7.4% | -2.7% | 6.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.56 | 0.56 | 0.58 | 0.64 | 0.57 |
| Current Ratio | 2.97 | 2.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.05B | $1.05B | $1.31B | $-2.49B | $-1.16B |
| Returns | |||||
| ROE | 1.7% | 1.7% | -5.0% | -1.8% | 4.4% |
| Valuation | |||||
| P/E | 41.91 | 41.91 | — | — | 23.10 |
| EV/EBITDA | 11.95 | 11.95 | 53.21 | 22.38 | 10.50 |
| P/B | 0.71 | 0.71 | 1.02 | 1.08 | 1.01 |
| Growth & Yield | |||||
| Revenue Growth | 9.2% | 9.2% | -6.9% | 0.2% | — |
| EPS Growth | 133.7% | 133.7% | -160.3% | -140.0% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
54.9%
EPS terminal req.
$583.87
Spread vs growth
78.8%
5Y implied EPS CAGR
35.1%
EPS terminal req.
$706.48
Spread vs growth
98.6%
10Y implied EPS CAGR
21.9%
EPS terminal req.
$1137.79
Spread vs growth
111.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-466.00 → 157.00
Residual
-24.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.